Neopharm Glioblastoma Drug Will Require Another Phase III Study, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Decision by agency to require another trial of cintredekin besudotox comes after the pivotal Phase III PRECISE study failed to meet its primary endpoint.
You may also be interested in...
Genentech Reports Positive Progression-Free Survival Results For Avastin In Brain Cancer Trial
Interim results of a Phase II study showed that 51 percent of patients receiving Avastin plus chemotherapy experienced six months of PFS, and 36 percent of patients taking Avastin alone had six-month PFS.
Genentech Reports Positive Progression-Free Survival Results For Avastin In Brain Cancer Trial
Interim results of a Phase II study showed that 51 percent of patients receiving Avastin plus chemotherapy experienced six months of PFS, and 36 percent of patients taking Avastin alone had six-month PFS.
NeoPharm Suspends Glioblastoma Trials Following Disappointing Phase III Results
Firm seeks meeting with FDA to determine path forward.